Premenstrual Syndrome Treatment Market Report and Forecast 2024-2032

Premenstrual Syndrome Treatment Market Overview

Premenstrual syndrome (PMS) involves a set of physical, emotional, and behavioural symptoms that occur in women 1–2 weeks before menstruation. These symptoms can range from mild discomfort, such as bloating and fatigue, to severe conditions affecting daily life. However, in some cases, a person can be affected by premenstrual dysphoric disorder (PMDD), which is a severe form of PMS characterised by heightened emotional and psychological symptoms, such as depression, anxiety, and irritability, significantly impairing daily functioning. The market value is driven by rising awareness, advancements in therapies, and a growing emphasis on women's health.

Premenstrual Syndrome Treatment Market Growth Drivers

Increasing Prevalence of PMS and PMDD

In a study conducted on more than 50,000 female participants, it was revealed that approximately 1.6% (which is equivalent to around 31 million women and girls globally) witness symptomatic premenstrual dysphoric disorder (PMDD). The rising incidence of PMS and its severe form, PMDD, among women of reproductive age is a significant growth driver.

Premenstrual Syndrome Treatment Market Trends

Premenstrual Syndrome Treatment Market Segmentation

Premenstrual Syndrome Treatment Market Share

Market Segmentation Based on Drug Class Set to Witness Substantial Growth

On the basis of drug class, the market can be segmented into analgesics, antidepressants, oral contraceptives and ovarian suppression agents among others. Analgesics are estimated to account for a significant market share as they are commonly used to alleviate physical symptoms of PMS, including cramps, headaches, and muscle pain. The easy accessibility of pain relievers like ibuprofen, naproxen, and aspirin along with their affordability and ease of purchase, further contribute to the market value of this segment.

Premenstrual Syndrome Treatment Market Analysis by Region

Based on region, the market is divided into the United States, EU-4 and the United Kingdom (Germany, France, Italy, Spain, and the UK), Japan, and India. Out of these, the United States dominates the market due to its well-established healthcare infrastructure, high awareness levels, and significant investments in women's health. In Europe, the United Kingdom is expected to lead the market share due to policies that advocate for women's health. Awareness campaigns play a pivotal role in encouraging diagnosis and treatment in the region.

Leading Players in the Global Premenstrual Syndrome Treatment Market

The key features of the market report include patent analysis, clinical trials analysis, grants analysis, funding and investment analysis, and strategic initiatives by the leading players. The major companies are:

Bayer AG

Bayer AG is a multinational life sciences company headquartered in Germany. It has expertise in pharmaceuticals, consumer health, and agricultural products. Its prominent offerings in the premenstrual syndrome (PMS) treatment market include Yaz and Yasmin, oral contraceptives that have shown efficacy in alleviating symptoms of PMS and premenstrual dysphoric disorder (PMDD) due to their hormonal regulation properties.

GSK plc

With a strong presence in the women's health segment, GSK plc focuses on innovative medicines, vaccines, and c...

AbbVie Inc.

AbbVie is based in Illinois, United States. It is a leading biopharmaceutical company that actively addresses ...

Mylan N.V.

Mylan N.V. is known for its broad portfolio of generic and branded medicines. Headquartered in Canonsburg, Pen...

*Please note that this is only a partial list; the complete list of key players is available in the full report. Additionally, the list of key players can be customized to better suit your needs.*

Other companies include Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries, Zydus Cadila, H. Lundbeck A/S and Merck & Co., Inc., among others.

Key Questions Answered in the Premenstrual Syndrome Treatment Market

• What was the premenstrual syndrome treatment market value in 2023?
• What is the premenstrual syndrome treatment market forecast outlook for 2024-2032?
• What are the regional markets covered in the EMR report?
• What is the market segmentation based on the drug class?
• What is the market breakup based on the type of drug?
• What is the market breakup based on the distribution channel?
• What are the major factors aiding the premenstrual syndrome treatment market demand?
• What are the market's major drivers, opportunities, and restraints?
• Which regional market is expected to lead the market share in the forecast period?
• Which country is expected to experience expedited growth during the forecast period?
• What are the major premenstrual syndrome treatment market trends?
• How does the rise in the geriatric population impact the market size?
• Who are the key players involved in the premenstrual syndrome treatment market?
• What are the current unmet needs and challenges in the market?
• How are partnerships, collaborations, mergers, and acquisitions among the key market players shaping the market dynamics?